Selected essential oil components as promising topical agents against Candida species: in vitro antifungal, antioxidant, and anti-inflammatory activities
DOI:
https://doi.org/10.12923/cipms-2026-0013Keywords:
eugenol, anti-candidal activity, radical scavenging action, cyclogenase-2 inhibitionAbstract
Candida species have emerged as a global threat due to their rapid worldwide spread and multidrug-resistant properties. Therefore, novel and more effective antifungal agents, including natural-based preparations, are being actively sought. Essential oil (EO) components, including α-bisabolol, carvacrol, eugenol, linalool, menthol, and thymol, were evaluated in vitro for their antifungal, antioxidant, and anti-inflammatory activities.
The aim of this study was to select EO compounds demonstrating the highest anticandidal activity together with promising antioxidant and anti-inflammatory properties for potential use as active ingredients in topical preparations. The activity of the tested EO compounds against five reference yeast strains belonging to Candida spp. was assessed in vitro using the broth microdilution method according to the recommendations of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI). All EO compounds demonstrated potential anticandidal activity, with minimum inhibitory concentrations (MICs) ranging from 0.25 to 4 mg/mL, and exhibited fungicidal properties (MFC/MIC = 1–4). The highest activity was observed for α-bisabolol (MIC = 0.25–1 mg/mL), followed by carvacrol (MIC = 0.25–2 mg/mL), thymol (MIC = 0.5–2 mg/mL), and eugenol (MIC = 0.5–2 mg/mL).
Eugenol exhibited the strongest antioxidant properties, even at a concentration of 0.1 mg/mL, as demonstrated by the DPPH assay. Moreover, this compound showed the highest anti-inflammatory activity, reflected by cyclooxygenase-2 (COX-2) inhibition of approximately 45% at a concentration of 0.5 mg/mL. Based on the obtained results, eugenol appears to be the most promising candidate for the development of topical preparations intended for the treatment of superficial infections caused by Candida spp.
References
1. Talapko J, Juzbašić M, Matijević T, Pustijanac E, Bekić S, Kotris I, Škrlec I. Candida albicans – the virulence factors and clinical manifestations of infection. J Fungi. 2021;7(2):79.
2. Bouopda Tamo SP. Candida infections: clinical features, diagnosis and treatment. Infect Dis Clin Microbiol. 2020;2(2):91-102.
3. Lalla RV, Patton LL, Dongari-Bagtzoglou A. Oral candidiasis: pathogenesis, clinical presentation, diagnosis and treatment strategies. J Calif Dent Assoc. 2013;41(4):263-268.
4. Staniszewska M. Virulence factors in Candida species. Curr Protein Pept Sci. 2020;21(3):313-323.
5. Mengesha BG, Conti HR. The role of IL-17 in protection against mucosal Candida infections. J Fungi. 2017;3(4):52.
6. Salazar SB, Simões RS, Pedro NA, Pinheiro MJ, Carvalho MFNN, Mira NP. An overview on conventional and non-conventional therapeutic approaches for the treatment of candidiasis and underlying resistance mechanisms in clinical strains. J Fungi. 2020;6(1):23.
7. Du H, Bing J, Hu T, Ennis CL, Nobile CJ, Huang G. Candida auris: epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog. 2020;16(10):e1008921.
8. de Sousa DP, Damasceno ROS, Amorati R, Elshabrawy HA, de Castro RD, Bezerra DP, et al. Essential oils: chemistry and pharmacological activities. Biomolecules. 2023;13(7):1144.
9. Karpinski TM. Essential oils of Lamiaceae family plants as antifungals. Biomolecules. 2020;10(1):103.
10. D’Agostino M, Tesse N, Frippiat JP, Machouart M, Debourgogne A. Essential oils and their natural active compounds presenting antifungal properties. Molecules. 2019;24(20):3713.
11. Benincá T, Schmidt L, Cardoso LT, Augusti PR, da Silva Malheiros P. Carvacrol as a food additive: toxicological aspects and the role of nanotechnology in enhancing its antimicrobial and antioxidant properties. Food Res Int. 2024;197:110745.
12. Drugs and Lactation Database (LactMed®). Bethesda (MD): National Institute of Child Health and Human Development; 2006. Oregano.
13. Dias IJ, Trajano ERIS, Castro RD, Ferreira GLS, Medeiros HCM, Gomes DQC. Antifungal activity of linalool in cases of Candida spp. isolated from individuals with oral candidiasis. Braz J Biol. 2018;78(2):368-374.
14. Zore G, Thakre A, Abdulghani M, Bhosle K, Shelar A, Patil R, et al. Menthol inhibits Candida albicans growth by affecting membrane integrity followed by apoptosis. Evid Based Complement Alternat Med. 2022;2022:1297888.
15. Bezerra CF, Júnior JGdA, Honorato RdL, Santos ATLd, Silva JCPd, Silva TG, et al. Antifungal effect of liposomal α-bisabolol and when associated with fluconazole. Cosmetics. 2021;8:28.
16. Didehdar M, Chegini Z, Shariati A. Eugenol: a novel therapeutic agent for the inhibition of Candida species infection. Front Pharmacol. 2022;13:872127.
17. European Committee for Antimicrobial Susceptibility Testing (EUCAST). Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. EUCAST Discussion Document E. Dis 5.1, Clin Microbiol Infect. 2003;9(1):1-7.
18. Wayne PA. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. M27-S4. 2012.
19. Baj T, Baryluk A, Sieniawska E. Application of mixture design for optimum antioxidant activity of mixtures of essential oils from Ocimum basilicum L., Origanum majorana L. and Rosmarinus officinalis L. Ind Crops Prod. 2018;115:52-61.
20. Leja KB, Czaczyk K. The industrial potential of herbs and spices - a mini review. Acta Sci Pol Technol Aliment. 2016;15(4):353–365.
21. Baser KHC, Buchbauer G. Handbook of Essential Oils: science, technology, and applications. CRC Press; 2020. p.1029-1040.
22. Aljaafari MN, AlAli AO, Baqais L, Alqubaisy M, AlAli M, Molouki A, et al. An overview of the potential therapeutic applications of essential oils. Molecules. 2021;26(3):628.
23. Pedroso RDS, Balbino BL, Andrade G, Dias MCPS, Alvarenga TA, Pedroso RCN, et al. In vitro and in vivo anti-Candida spp. activity of plant-derived products. Plants. 2019;8:494.
24. Stringaro A, Colone M, Cecchetti S, Zeppetella E, Spadaro F, Angiolella L. “In vivo” and “in vitro” antimicrobial activity of Origanum vulgare essential oil and its two phenolic compounds on clinical isolates of Candida spp. Arch Microbiol. 2022;205(1):15.
25. Kaskatepe B, Aslan Erdem S, Ozturk S, Safi Oz Z, Subasi E, Koyuncu M, et al. Antifungal and anti-virulent activity of Origanum majorana L. essential oil on Candida albicans and in vivo toxicity in the Galleria mellonella larval model. Molecules. 2022;27(3):663.
26. El-Shiekh RA, Meselhy MR, Elshimy R, Ibrahim MA, Ali ME, Hassanen EI. Plumieride as a novel antifungal and anti-inflammatory iridoid against superficial candidiasis in mice. BMC Complement Med Ther. 2024;24(1):224.
27. El Mihyaoui A, Esteves da Silva JCG, Charfi S, Candela Castillo ME, Lamarti A, Arnao MB. Chamomile (Matricaria chamomilla L.): a review of ethnomedicinal use, phytochemistry and pharmacological uses. Life. 2022;12(4):479.
28. Kowalczyk A, Przychodna M, Sopata S, Bodalska A, Fecka I. Thymol and thyme essential oil – new insights into selected therapeutic applications. Molecules. 2020;25(18):4125.
29. Sharifi-Rad M, Varoni EM, Iriti M, Martorell M, Setzer WN, Del Mar Contreras M, et al. Carvacrol and human health: a comprehensive review. Phytother Res. 2018;32(9):1675-1687.
30. Ulanowska M, Olas B. Biological properties and prospects for the application of eugenol – a review. Int J Mol Sci. 2021;22(7):3671.
31. Vassiliou E, Awoleye O, Davis A, Mishra S. Anti-inflammatory and antimicrobial properties of thyme oil and its main constituents. Int J Mol Sci. 2023;24(8):6936.
32. Subudhi L, Thatoi H, Banerjee A. Anti-inflammatory activity of essential oil from medicinal plants: an insight into molecular mechanism, in-silico studies and signaling pathways. Phytomedicine. 2025;138:156364.
33. Valdivieso-Ugarte M, Gomez-Llorente C, Plaza-Díaz J, Gil Á. Antimicrobial, antioxidant, and immunomodulatory properties of essential oils: a systematic review. J Nutr. 2019;11(11):2786.
34. das Chagas Pereira de Andrade F, Mendes AN. Computational analysis of eugenol inhibitory activity in lipoxygenase and cyclooxygenase pathways. Sci Rep. 2020;10(1):16204.
35. Barboza JN, da Silva Maia Bezerra Filho C, Silva RO, Medeiros JVR, de Sousa DP. An overview on the anti-inflammatory potential and antioxidant profile of eugenol. Oxid Med Cell Longev. 2018;2018:3957262.
36. Biernasiuk A, Baj T, Malm A. Clove essential oil and its main constituent, eugenol, as potential natural antifungals against Candida spp. alone or in combination with other antimycotics due to synergistic interactions. Molecules. 2022;28(1):215.
37. Didehdar M, Chegini Z, Shariati A. Eugenol: a novel therapeutic agent for the inhibition of Candida species infection. Front Pharmacol. 2022;13:872127.
38. European Medicines Agency (EMA). Committee on Herbal Medicinal Products (HMPC). Assessment report on Syzygium aromaticum (L.) Merill et L.M. Perry, flos and Syzygium aromaticum (L.) Merill et L.M. Perry, floris aetheroleum. EMA/HMPC/543946/2010; 2011.
39. Abdou A, Elmakssoudi A, El Amrani A, Jamal Eddine J, Dakir M. Recent advances in chemical reactivity and biological activities of eugenol derivatives. Med Chem Rev. 2021;30:1011-1030.
40. Chilamakuri SN, Kumar A, Nath AG, Gupta A, Selvaraju S, Basrani S, et al. Development and in-vitro evaluation of eugenol-based nanostructured lipid carriers for effectual topical treatment against C. albicans. J Pharm Sci. 2024;113(3):772-784.
41. Dubey P, Kumar A, Vaiphei KK, Basrani S, Jadhav A, Wilen CE, et al. A poly-δ-decalactone (PDL) based nanoemulgel for topical delivery of ketoconazole and eugenol against Candida albicans. Nanoscale Adv. 2024;6(21):5322-5336.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Bartłomiej Pawlicki, Anna Biernasiuk, Tomasz Baj, Katarzyna Suśniak, Anna Malm (Autor)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
